Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS)

Abstract only

Saved in:
Bibliographic Details
Published in:JOURNAL OF CLINICAL ONCOLOGY Vol. 33; no. 15_suppl; p. 5564
Main Authors: Roncolato, Felicia T, O'Connell, Rachel, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sjoquist, Katrin Marie, Gillies, Kim, Butow, Phyllis, Stockler, Martin R., King, Madeleine Trudy, Friedlander, Michael
Format: Journal Article Conference Proceeding
Language:English
Published: 20-05-2015
Subjects:
Medicin och hälsovetenskap
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2015.33.15_suppl.5564